The University of Vienna was founded by Duke Rudolph IV in 1365. It is the oldest university in the German-speaking world and one of the largest in Central Europe. Currently, 91,700 students are enrolled at the University of Vienna. With 9,500 employees, including about 6,700 academics, the University of Vienna is the largest teaching and research institution in Austria. The University of Vienna encompasses a broad spectrum of scientific disciplines, ranging from theology, jurisprudence, economics, computer science, to the humanities and to the social and natural sciences. The academic project coordinator Thierry Langer is head of the Department of Pharmaceutical Chemistry at the Faculty of Life Sciences.
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 100,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life. With a presence in more than 100 countries and industrial sites in more than 40 countries, our industrial network, know-how and teams deliver health solutions to millions of individuals with high quality and maximum safety, regardless wherever they are manufactured. We concentrate our research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide.
The University of Eastern Finland is one of the largest universities in Finland. We show courage in crossing academic boundaries and our interdisciplinary approach is internationally recognised. Our research is ranked among the best in the world in several fields. As a multidisciplinary university, we train experts for the various sectors of society. We seek solutions to global challenges through multidisciplinary research and education. In collaboration with our partners, we generate new knowledge, expertise and innovations.
University of Belgrade is the largest university in the Balkans, with more than 80.000 students, 320 programs offered, and a staff of 4.300 researchers. In 2017, University of Belgrade was among 200 best universities in subject of Pharmacy & Pharmaceutical Sciences (Shanghai Ranking’s). The Department of Pharmacology at the Faculty of Pharmacy is focused on the experimental analysis of the influence of psychiatric and other drugs on rodent behaviour, with an emphasis on treatment formulation, brain exposure and age/gender differences.
ALCEDIAG research focuses on a specific subcategory of biology called epigenetics. Whereas genetics is the study of genes and heredity, epigenetics focuses on a complementary, yet not less important aspect – how environmental factors switch genes on and off and affect gene expression. Epigenetic processes are reversible and dynamic, as they evolve over time. Their occurrence is affected by environmental factors, in the broadest sense. ALCEDIAG’s epigenetic biomarkers allow a dynamic approach of diagnostics, taking into account the patients’ condition, the potential progression of the disease as well as the impact of treatment.
University of Clermont Auvergne (UCA) is committed to developing educational programmes for an international public (dual-award programmes) and to enhancing its research at an international level. These two drivers have the wide support of programmes which consolidate the position of our institution in the international environment through the participation of different consortiums in European programmes and by our presence in cooperative academic associations such as AUF and EUA, and through our more and more active participation in international research and cooperation projects. Since its creation, UCA has embraced the two main European political roadmaps for 2014-2020 through the Erasmus+ and Horizon 2020 programmes. UCA is at the heart of the Erasmus Internship Consortium for the whole catchment area of Clermont Ferrand.
Biovista is a pioneer of AI and systematic drug repositioning. We apply our systematic discovery Artificial Intelligence platform to develop our pipeline of repositioned drug candidates in disease areas such as neurodegenerative diseases, epilepsy, oncology and orphan diseases. We also work with our collaborators to proactively position and to reposition their own assets, whether new chemical entities or existing compounds. Our scientists use Biovista’s technology platform to analyze massive data resources and identify non-obvious, mechanism-of-action based associations between compounds, molecular targets and diseases.
ICETA is a non-profit Institution that supports R&D programs granted to research groups of University of Porto (UPorto), Portugal’s 2nd largest university and biggest producer of science. Toxicology Group (TOXG), sited at Faculty of Pharmacy of UPorto, integrates UCIBIO-REQUIMTE Associated Lab, one of ICETA’s research centres, which ranked as Outstanding and in top 3% of all Units in Portugal in the latest national/European research unit evaluation. TOXG has a long-term established in vitro/in vivo Toxicology expertise with high- impact input to substance safety profiling/efficacy assessment of pharmacologically active drugs.
The University of Florence is an important and influential centre for research and higher training in Italy, with 1,800 lecturers and internal research staff, 1,600 technical and administrative staff, and over 1,600 research assistants and doctoral students. It offers a wide range of study programmes at various levels and in all areas of knowledge. Over 130 Degree courses (First and Second Cycle, corresponding to Bachelor’s and Master’s Degrees) organised in 10 Schools, with a population of about 51,000 enrolled students, one-fourth of which come from outside of Tuscany. There are over 9,000 degrees awarded each year in Florence. According to the alumni data, the percentage of students who are in the workforce one year after their First Level degree is above national average.
Founding faculty of the University of Vienna in 1365 and independent since 2004 the Medical University of Vienna (briefly: MedUni Vienna) is today one of the most traditional medical training and research facilities in Europe. It is today the largest medical training institute in the German-speaking area with about 8,000 students. With its 26 university hospitals, three clinical institutes, 12 theoretical medicine centres and numerous highly specialised laboratories, it is included among the most important cutting-edge research institutes of Europe in the area of biomedicine. Its own laboratory building with highly specialised “Core Facilities” was inaugurated in June 2010 with the “Anna Spiegel Research Building”.
Inte:Ligand assists scientists and management in the pharmaceutical, life science and cosmetic industries to improve their efficiency in identifying new bio-active molecules. We develop and deliver innovative scientific software solutions as well as provide expert consulting facilitating the decision making process for prioritizing compounds for further experimental assessment.
Uppsala University is the Nordic region’s oldest university – founded in 1477 – and is ranked among the top 100 universities in the world. There are more than 40,000 students here and they are seen, heard and make their mark everywhere. The University’s nearly 5,000 researchers and teachers conduct world-leading research and offer a seemingly endless number of courses. Among the University’s alumni there are 15 Nobel Prize laureates, of which 8 received their prizes for discoveries made during their time at Uppsala University. Carl Linnaeus, Anders Celsius and Olof Rudbeck the Elder are a few examples of prominent scientists in Uppsala University’s history.
At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are. We combine a unique range of knowledge, skills and experience with a passion for following the science. We work alongside scientists at leading institutions to better understand disease, identify potential new drugs and accelerate drug development. We’re also pioneers in creating a more open research environment.
Cellular Dynamics International (CDI), a FUJIFILM company, is a leading developer and supplier of human cells used in drug discovery, toxicity testing, and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, CDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company’s inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development.
At MSD (Merck in the US), we are inspired by a shared vision and mission to save and improve lives. To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future. To discover, develop and provide innovative products and services that save and improve lives around the world.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs. We reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our researchers combine imagination with the rigor of collaborative science to find better treatments for disease.
At Pfizer we strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of medicines and vaccines that have the potential to save lives, prevent illness and improve health and wellbeing. But we don’t achieve this alone. Collaborations with healthcare providers, patient communities, academia, and policy makers are fundamental to bringing new medicines to patients.
UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science. UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.